Globalpharma Boosts UAE Pharma with 4 MoUs at Make it in the Emirates 2025
These agreements aim to localize manufacturing and foster innovation, strengthening the nation's pharmaceutical independence and capabilities
Globalpharma, the UAE’s premier pharmaceutical manufacturer and a fully owned subsidiary of Dubai Investments PJSC, has signed four major Memorandums of Understanding (MoUs) during the 2025 edition of the Make it in the Emirates Forum. These partnerships highlight the UAE’s growing influence as a regional centre for pharmaceutical innovation, manufacturing, and healthcare advancement.
Customized Agreements with Global Partners
Each MoU was individually signed, showcasing Globalpharma’s personalized strategy in forming strategic alliances. The company entered into agreements with four international partners: PharmaPrimes Laboratories (Jordan), Nerhadou International (Egypt), Aora Health (Spain), and BioSyent Pharma Inc. (Canada). The signing ceremonies for the first three took place in the presence of H.E. Dr. Thani Al Zeyoudi, UAE Minister of State for Foreign Trade and Chairman of the Emirates Drug Establishment. These deals focus on areas such as technology transfer, licensing, local production, and supply, all aligned with the UAE’s broader industrial goals to foster local manufacturing and reduce dependence on imported healthcare solutions.
“The strategic collaborations announced by Globalpharma during ‘Make it in the Emirates’ reflect the UAE’s commitment to strengthening domestic pharmaceutical manufacturing and reducing reliance on imports. These partnerships embody the core goals of the ‘Make it in the Emirates’ initiative—empowering local industry, accelerating innovation, and enhancing the country’s position as a global hub for high-quality, future-ready healthcare solutions,” stated His Excellency Dr. Thani Al Zeyoudi, UAE Minister of State for Foreign Trade and Chairman of the Emirates Drug Establishment.
"Dubai Investments’ long-term strategy is rooted in enabling sectors that drive national progress, and healthcare is central to that vision. These strategic partnerships by Globalpharma reflect the commitment to advancing the UAE’s industrial capabilities, promoting knowledge transfer, and building a resilient pharmaceutical ecosystem that supports regional health security and innovation-driven growth," said Mohammed Saeed Al Raqbani, General Manager of Dubai Investments Industries and Masharie and Board Director at Globalpharma.
Strengthening Biosimilar Drug Infrastructure with PharmaPrimes
In a key development, Globalpharma partnered with PharmaPrimes Laboratories, a leading contract research organization based in Jordan, to build local capabilities for the testing and batch release of biosimilar drugs. This initiative aims to create a robust quality infrastructure within the UAE, improve access to affordable biosimilar treatments, and enhance pharmaceutical competitiveness across the GCC region.
Expanding Nutraceutical Offerings with Nerhadou International
Globalpharma has also joined forces with Nerhadou International, one of Egypt’s top nutraceutical companies, to bring a diverse range of over-the-counter (OTC) and health-focused products to the UAE. The partnership is set to play a pivotal role in advancing preventive healthcare and encouraging healthier lifestyles throughout the region.
Co-Developing Functional Supplements with Spain’s Aora Health
Further extending its reach in wellness innovation, Globalpharma announced a partnership with Spain-based Aora Health, recognized for its scientific approach to functional supplements. This collaboration will focus on the co-development and local manufacturing of high-quality, preventive health products — facilitating faster market entry of European-grade wellness solutions across the UAE and wider MENA region.
Launching FeraMAX® in UAE Through BioSyent Agreement
Completing the series of MoUs, Globalpharma signed a Licensing and Supply Agreement with Canada’s BioSyent Pharma Inc., known for its portfolio of niche, effective pharmaceutical products. The agreement covers FeraMAX®, a patented oral iron supplement known for its superior absorption and minimal gastrointestinal side effects. Globalpharma will handle the secondary packaging and marketing of FeraMAX® within the UAE, contributing to improved patient care through accessible and advanced therapeutic options.
Comments